This review describes our recent eorts in the development of novel therapies for cancer. Our primary approach is to design synthetic agents that antagonize the function of growth factors that are critically involved in oncogenesis and angiogenesis. We achieve this by designing synthetic molecules that can recognize the exterior surface of the growth factor and so block the interaction with its receptor tyrosine kinase. A key step is the construction of synthetic agents that contain a large (4400A Ê 2 ) and functionalized surface area to recognize a complementary surface on the target growth factor. In the course of this work we have discovered a molecule, GFB-111, that binds to PDGF, prevents it from binding to its receptor tyrosine kinase, blocks PDGF-induced receptor autophosphorylation, activation of Erk1 and Erk2 kinases and DNA synthesis. The binding anity for PDGF is high (IC 50 =250 nM) and selective over EGF, IGF-1, aFGF, bFGF and HRGb. In nude mouse models GFB-111 also shows signi®cant inhibition of tumor growth and angiogenesis. Oncogene (2000) 19, 6566 ± 6573.
Introduction
The search for new therapies in the war against cancer remains a top priority in biomedical research. In many cases current clinical therapies have changed little in several decades. The key to successfully developing novel clinical strategies against these cancers is twofold. First, critical protein targets that are known to be essential in the growth of tumors must be identi®ed and validated as cancer therapy targets. Second, a novel approach to disrupting the function of these essential targets must be developed and shown to selectively block the growth of transformed cells. Our strategy is to disrupt the interaction of key growth factors with their receptor tyrosine kinase (RTK) targets in the cell membrane. To this end, we use an entirely novel strategy based on the design of synthetic agents that selectively and strongly bind to the surface of the growth factor and so block its oncogenic signaling function (Figure 1 ).
Our primary goal is to design synthetic agents that can recognize the exterior surface and antagonize the function of growth factors that are critically involved in oncogenesis. In our early work we have placed particular focus on platelet derived growth factor (PDGF) and its complementary receptor tyrosine kinase, platelet derived growth factor receptor (PDGFR). Overexpression of PDGFR is seen in many carcinomas and some cancer patients have high serum levels of PDGF. These elevated levels of PDGF and PDGFR in cancer patients also correlate with poor response to chemotherapy and shorter survival times. Synthetic agents that can block the uncontrolled signaling function of overexpressed receptor tyrosine kinases have the potential to slow the growth of tumors and greatly improve the quality of life for cancer patients (Figure 1 ).
Receptor tyrosine kinases as targets for cancer chemotherapy
Interaction of a quiescent cell with an external growth factor such as PDGF or epidermal growth factor (EGF) results in the activation of a complex network of signaling pathways that lead ultimately to cell division. The ®rst step in this pathway involves the binding of the growth factor to the extracellular region of a membrane bound protein receptor tyrosine kinase (PDGFR or EGFR). Binding leads to dimerization of the receptor and activation of autophosphorylation of tyrosines on the receptor surface (Rockwell and Goldstein, 1995) . This initiates the recruitment of several signaling proteins (including phosphatidylinositol-3-kinase, Src, Grb2/m-SOS-1 (a nucleotide exchange factor for Ras) and signal transducers and activators of transcription (STATs)) each of which contains src-homology-2 (SH-2) domains. Binding of the SH-2 regions of these proteins to the phosphotyrosines on the RTKs activates several pathways that are critical for triggering the cell cycle machinery.
The most well studied pathway passes through the GTP-binding protein Ras and activates the mitogen activated kinase (MAPK) cascade and subsequently transcription factors in the nucleus (Figure 2) . Mutations in the Ras protein are present in 30% of human cancers and have been the subject of intense recent interest. We have reported extensively over the past seven years on the design of inhibitors for farnesyltransferase, a key enzyme in the posttranslational modi®cation of Ras . These compounds not only disrupt Ras farnesylation in whole cells but also block the growth of human tumors in nude mice models, and are on the verge of phase I clinical trials (Sun et al., 1999) . None of this work will be discussed here, however it provides a proof of Oncogene (2000) 19, 6566 ± 6573 ã 2000 Macmillan Publishers Ltd All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc *Correspondence: SM Sebti and AD Hamilton principle for targeting RTK signaling pathways in cancer therapy.
The primary focus of this review is the ®rst step in the aberrant cell signaling pathways that lead to uncontrolled proliferation and cancer, namely the interaction of growth factors with RTKs. For example, PDGF, which plays an important role in many human malignancies (Heldin, 1992) exists in three isoforms (homodimers PDGF-AA and PDGF-BB and heterodimer PDGF-AB) and exerts its biological eects via speci®c binding to PDGF receptors (PDGFRs) (Hart et al., 1988) . Overexpression of PDGFR is seen in certain breast (Seymour et al., 1993) and ovarian (Henriksen et al., 1993) carcinomas as well as high serum levels of PDGF. Furthermore, elevated levels of PDGF and PDGFR in breast cancer patients correlate with poor response to chemotherapy and shorter survival times (Seymour et al., 1993) . The design of PDGF antagonists that can inhibit ligand-induced receptor activation has been suggested as a route to new anti-cancer drugs (Fiona and William, 1994) . This strategy is supported by antibodies against PDGF which show anti-mitogenic activity (Johnson et al., 1985) and a 110 kDa soluble form of the receptor has been shown to inhibit both the binding of PDGF-BB to PDGFR and the receptor tyrosine kinase activity (Duan et al., 1991) . These results strongly suggest that PDGF and PDGFR represent compelling targets for anti cancer drug design. Furthermore, PDGF has been shown to be critically involved in the angiogenesis process. PDGF can not only stimulate the proliferation of endothelial cells but also can stimulate the secretion of vascular endothelial growth factor. Moreover, PDGF knockout mice are de®cient in processes of angiogenesis (Blaskovich, 2000) .
The crystal structure of PDGF shows it to be a head-to-tail dimer, with each peptide folded into two long antiparallel pairs of b-strands with three intramolecular disul®de bonds ( Figure 3 ) (Oefner et al., 1992) . The three surface loops connecting the strands (designated as I, II and III) are clustered at one end of the elongated dimer upon dimerization. Mutational analyses of individual amino acid residues or short peptide sequences in PDGF-B (Fenstermaker et al., 1993; Ostman et al., 1991; LaRoclelle et al., 1992) have indicated that the key binding regions on PDGF occur in loops I and III. There is also some indication that residues from loop II from the other subunit of the dimer may also be involved in receptor binding (Anderson et al., 1995) . Inspection of the X-ray structure of PDGF-BB shows that the hairpin turns in loops I and III are separated by 10-12A Ê . Loop I projects a hydrophobic sequence (ANFLVW), loop III contains a highly cationic region (EIVRKKP) and loop II has a combination of both (NNRNV) (Engstom et al., 1992) .
Design of novel synthetic agents for protein surface binding
Protein recognition can be divided into two categories in terms of the interaction sites: (1) interactions that occur inside proteins, e.g. enzyme active sites; (2) interactions that occur on the surface of proteins. During the past two decades large numbers of synthetic molecules targeted to disrupt interior protein interactions have been shown to have medically important biological activities (Babine and Bender, 1997). However, arti®cially designed molecules that target the protein surface and disrupt its biological activity are rare (Hartwell et al., 1997) . Considering the unique composition of charged, hydrophobic and hydrophilic domains on every protein's surface, synthetic molecules that match the electrostatic features and topology of the protein targets might be expected to bind to the exterior and sterically prevent protein ± protein interactions.
A model for protein surface recognition is provided by the immune system which generates a large number of antibodies that show high sequence and structural selectivity in binding to a range of protein surfaces (Brandon and Tooze, 1991) . Our approach to growth factor binding agents involves the attachment of several peptide loops onto a core scaold (Figure 4a ) in direct analogy to the six hypervariable loops that are (Figure 4b ). The advantages of using this design for the recognition of protein surfaces are fourfold: (1) large surface areas can be created (4400 A Ê 2 ); (2) modular design enables us to generate a large diversity from a small number of cyclic peptide or scaold components; (3) various non-natural groups can be incorporated into the loop structures and (4) scaolds are relatively¯exible which allows an`induced ®t' mechanism of binding.
We have recently prepared the ®rst of a new class of protein surface receptors involving the attachment of four peptide loops to a central scaold (based on the calix[4]arene unit 1) (Hamuro et al., 1997) . The peptide loop component was based on a cyclic hexapeptide 2 in which two residues were replaced by a 3-aminomethylbenzoyl (3 amb) dipeptide mimetic (Bach et al., 1994) containing a 5-amino substituent for linkage to the scaold. The resulting molecule 3 contains a functionalized surface approximately 400A Ê 2 in area. The GDGD sequence in 2 was chosen to provide a surface containing both negatively charged and hydrophobic regions that would bind to a complementary surface on a target protein. We have prepared analogs of 3 in which the sequence of the cyclic peptide is varied to include anionic, hydrophobic and cationic residues, such as GDGD (3), GDGY (5), GKGF (6) and GKGK (7). This provided us with a ®rst generation library of protein binding agents that were screened for their ability to bind to the surface of PDGF (Scheme 1).
Disruption of growth factor signaling by synthetic protein binding agents
Our ®rst assessment of whether these molecules were able to interact with growth factors involved testing their ability to block PDGF-induced autophosphorylation of PDGFR. NIH3T3 cells were treated with the synthetic growth factor binding agents and PDGF (30 ng/ml) for 10 min, followed by lysis of the cells, SDS ± PAGE and Western blot analysis using an antiphosphotyrosine antibody. Figure 5 shows the ability of the ®rst generation GFB series at 5 mM concentrations to inhibit PDGF stimulation of the receptor tyrosine phosphorylation. We found that the molecule containing GlyAspGlyTyr (GDGY) sequences in each of the four peptide loops of (GFB-111) blocked PDGF-BB-stimulation of PDGF receptor tyrosine autophosphorylation with an IC 50 value of 250 nM (Table 1) . This fourfold symmetrical arrangement of negative and hydrophobic residues shows a strong complementary to the region of PDGF that interacts with the recognition surface of PDGFR. The critical receptor binding area on PDGF-BB contains lysine and arginine residues as well as a signi®cant number of amino acids with hydrophobic side chains. Mutational analysis has shown that growth factor binding to its receptor diminishes when these residues are changed (Oefner et al., 1996; Anderson et al., 1995) .
Similarly, there is a loss in binding ability when the key Asp and Tyr residues in the cyclic peptides in GFB-111 are changed. For example, substitution of negatively charged Asp by positively charged Lys, as with GFB-115 (GKGF) (IC 50 =50 mM) and GFB-116 (GKGK) (IC 50 =40 mM), causes an almost 200-fold reduction in antagonist potency. Changing the hydrophobic Tyr for Asp, as in GFB-107 (GDGD) (IC 50 =2.5 mM), leads to an order of magnitude loss in activity. The speci®c sequence of the cyclic peptide also appears to be important. Rearranging the anionic and hydrophobic residues in the four cyclic peptides as in GFB-122 (GDDY) (IC 50 =1.7 mM) leads to a sevenfold reduction in binding activity compared to GFB-111 (GDGY) ( Table 1 ). Further insight into the mechanism by which GFB-111 was able to disrupt PDGF induced PDGFR phosphorylation was gained from a direct binding assay between [I-125]-labeled PDGF and PDGFR on the surface of NIH3T3 cells. Under normal circumstances [125-I]-PDGF-BB binds eectively to the receptor on the surface of NIH3T3 cells. However, pre-treatment with increasing concentrations of GFB-111, caused a decrease in PDGF-BB binding that followed normal dose dependent behavior ( Figure 6 ). We measured an IC 50 value for disruption of PDGF binding of 250 nM which corresponds well with the value measured for GFB-111 in the PDGFR tyrosine phosphorylation assay (Table 1) . A similar experiment using GFB-116 (Figure 6 ) showed that PDGF-BB binding to its receptor was not blocked and con®rmed the importance of the GDGY sequence. Excellent protein binding selectivity was also established in these experiments. GFB-111 (10 mM) was found to have no eect on the binding of (Figure 7) . This selectivity for PDGF over related growth factors such as EGF, and to a lesser extent VEGF, is consistent with dierences in their overall structure, particularly in areas involved in receptor binding. The critical residues for PDGF binding to its receptor are a Scheme 1 series of hydrophobic and positively charged amino acids in loops I and III of one monomer, and loop II of the head-to-tail linked second monomer in dimeric PDGF (Oefner et al., 1996; Anderson et al., 1995) . VEGF shares some structural homology with PDGF, but its receptor binding regions are made up principally of hydrophobic and negatively charged residues (Muller et al., 1997) . EGF has a completely dierent structure to PDGF and VEGF. The critical receptor binding region has been shown to contain several hydrophobic groups and a positively charged arginine residue (Arg41) (Campion and Niyogi, 1994) . The receptor binding domains of these three growth factors are thus quite dierent suggesting that the negatively charged and hydrophobic surface of GFB-111 achieves its selectivity by matching the positive and hydrophobic surface of PDGF.
There is a strong possibility that the amphipathic GFB-111 is binding to the cationic and hydrophobic regions of the PDGF dimer and in doing so blocking its association to the receptor surface. A calculated structure for the interaction of this region of PDGF (using the crystal structure coordinates) with GFB-111 is shown in Figure 8 . Similar interactions have been proposed for suramin binding to PDGF (Middaugh et al., 1992) and heparin binding to ®broblast growth factor (Thompson et al., 1994) .
These early results clearly pointed to an interaction between GFB-111 and PDGF and a disruption of the initial activation of PDGFR tyrosine phosphorylation. The next question concerned whether this complex formation would lead to a disruption in downstream cell signaling pathways (Figure 2) . We assessed the ability of GFB-111 to block growth factor-stimulated tyrosine phosphorylation of several receptor tyrosine kinases and subsequent activation of two mitogenactivated protein kinases (MAPK), Erk1 and Erk2. Treatment of starved NIH3T3 cells with PDGF-BB led to PDGFR autophosphorylation and Erk1/Erk2 activation ( Figure 9 ). However, in the presence of GFB-111 (0.1 ± 10 mM) there was a concentrationdependent inhibition of activation of Erk1 and Erk2 (IC 50 of 0.8 and 1.2 mM, respectively). A similar eect was seen on PDGF-AA stimulation of PDGF receptor phosphorylation and Erk1/Erk2 activation. However selectivity among dierent growth factors was seen since GFB-111 at concentrations as high as 100 mM did not aect the ability of EGF to stimulate EGFR tyrosine phosphorylation and Erk1/Erk2 activation. As a positive control a known EGFR tyrosine kinase inhibitor, PD158780, blocks EGFR tyrosine phosphorylation and Erk1/Erk2 activation (Figure 9 ). Furthermore, IGF-1-, aFGF-, bFGF-and HRGb-activation of Erk1/Erk2 was minimally aected by GFB-111 at concentrations as high as 100 mM (Figure 9) . The results are consistent with the earlier radiolabeled growth factor data which showed a signi®cant protein binding selectivity in the eects of GFB-111.
Anticancer activity of GFB-111
The above investigations showed that GFB-111 was able to bind to PDGF and block in a potent and selective manner PDGF-dependent signaling. However, a critical test for the strategy concerned the ability of GFB-111 to interfere with the function of PDGF in animal models. PDGF is well known to contribute to cancer cell growth by, in part, stimulating angiogenesis. This prompted us to investigate the in vivo anti-tumor Figure 10 shows that the treated group exhibited a dosedependent inhibition of tumor growth of 56, 81 and 88%, respectively. Daily treatment with GFB-111 went on for more than one month yet there were no signs of gross toxicity among the animals. This provides good support that the molecules are exerting their eect through interference with a speci®c growth mechanism rather than through any systemic toxicity. At the end of the experiment the tumors from the mice were extracted and analysed to determine the extent of PDGF-dependent signaling. Figure 10 shows that Erk1/Erk2 activation was diminished in the tumors treated with 50 mg per kg and almost completely blocked in those treated with 100 and 200 mg per kg, con®rming that our designed molecule was causing an inhibition of the PDGF-activated signaling pathway. Figure 9 Eects of GFB-111 on growth factor stimulated receptor tyrosine autophosphorylation and activation of MAPK Similar growth inhibition in nude mice was seen with other tumor cell lines, such as human lung adenocarcinoma A-549 and the rat glioma C6. However, little eect was seen on the growth of the human medulloblastoma DaOY (Table 2) . Although excellent inhibition of tumor growth by GFB-111 was seen, the mechanism by which the synthetic molecule exerts this eect was not clear. An intriguing result is the equipotent eect seen with tumors that depend on PDGF (U87) and those that do not (A549), suggesting an alternative mechanism to direct eects on the tumor cells. One possibility was that GFB-111 interferes with the growth of blood vessels in the tumor since PDGF is known to be important in promoting angiogenesis. In the U87MG nude mouse xenograft experiment, tumor biopsy specimens were taken at the end of the experiment, ®xed and processed into paran blocks. The tissue sections were immunostained with the vascular marker Factor VIII and are shown in Figure 11 . Tumors from animals treated with 50, 100 and 200 mg per kg GFB-111 showed a dose dependent decrease in immunostaining, in marked contrast to tumors from the untreated animals which showed extensive staining (vascularization). A more detailed quanti®cation of microvessels in the tumor preparations showed that U87MG and A-549 tumors were sensitive to GFB-111 inhibition of angiogenesis whereas DaOY tumors showed no eect.
Conclusion
In this review we have described the recent progress that we have made in establishing a novel approach to disrupting the interaction between a growth factor and its receptor tyrosine kinase. We have outlined a strategy that mimics the use of peptide loop recognition domains as seen in antibody complementary determining regions. The synthetic growth factor binding agents (GFBs) are composed of four synthetic peptide loop domains linked to a core calixarene based scaold. The potential of the approach has been ®rmly established by targeting the interaction between PDGF and its receptor tyrosine kinase. We show that one eective member of the GFB family is able not only to block the interaction of PDGF with PDGFR but also to inhibit its signaling function. This potent eect further translates into an ability to slow down the growth of human tumors in nude mouse models through an antiangiogenic mechanism.
This study represents the ®rst example of a potential new approach to controlling cell signaling through the selective disruption of protein ± protein interactions. The key to the strategy will be to develop a range of GFBs with dierent surface recognition characteristics that can be then applied to dierent growth factors. We are currently investigating dierent core scaold structures and alternative recognition elements that will enhance selective binding to growth factor surfaces.
